New Data at DDW 2025 Further Demonstrates the TissueCypher Test’s Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Additionally, an expert physician panel convened by EndoscopyNow will host a product…
Pfizers BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial…
Pfizers BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial…
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy…
Patients experienced a 38% reduction in the risk of disease progression or…
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
January 21, 2025 19:00 ET | Source: ArriVent BioPharma, Inc. Exclusive global…
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
January 21, 2025 17:00 ET | Source: Adagene Inc. SAN DIEGO and…
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review…